Avenue Therapeutics完成了SBMA的1b/2a期试验，并计划进行癫痫的2a期试验，等待融资。 Avenue Therapeutics completes Phase 1b/2a trial for SBMA and plans Phase 2a trial for epilepsy, pending financing.
Avenue Therapeutics已经完成了AJ201治疗脊髓和延髓肌萎缩症（SBMA）或肯尼迪病的1b/2a期临床试验的最后一次患者就诊，预计将在2024年下半年获得顶线数据。 Avenue Therapeutics has completed the final patient visit in its Phase 1b/2a clinical trial of AJ201 for spinal and bulbar muscular atrophy (SBMA), or Kennedy's Disease, with topline data expected in H2 2024. 该公司计划开始对和其他发作疾病的BAER-101的第二阶段试验,但需要进一步的资金. The company aims to start a Phase 2a trial of BAER-101 for epilepsy and other seizure disorders, subject to further financing. 对于静脉注射特拉马多尔治疗急性术后疼痛的第三阶段研究,Avenue Therapeutics还同意了一项安全研究方案和统计分析方法,等待额外的资金或合作伙伴关系. Avenue Therapeutics also agreed on a safety study protocol and statistical analysis approach for the Phase 3 study of intravenous tramadol for acute post-operative pain, pending additional financing or partnership. 该公司在2024年从一项证书行使交易中获得了4400万美元的毛利,截至2024年6月30日,现金和现金等价总额为4900万美元. The company raised $4.4m in gross proceeds from a warrant exercise transaction in 2024, and cash and cash equivalents totaled $4.9m as of June 30, 2024.